Drug Trial Radar · NCT03716739
Improving Quality of Life of Prostate Cancer Survivors With Androgen Deficiency
Last checked: Nov 20, 2026Latest source record: Jul 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
136
Actual
Start
Mar 19, 2019
Primary completion
May 16, 2025
Study completion Jul 16, 2025
Sponsor
- Lead sponsor
- Dana-Farber Cancer InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute on Aging (NIA)
- First posted
- Oct 23, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Supportive care
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this phase II trial is to determine the efficacy and safety of testosterone replacement therapy (TRT) in improving the symptoms of androgen deficiency and health-related quality of life in men with prostate cancer who have undergone radical prostatectomy.
Conditions
- Prostate Cancer
Interventions
Testosterone Cypionate 100 MG/MLDrug
100 mg testosterone cypionate administered by intramuscular injection weekly for 12 weeks.
PlaceboDrug
Placebo administered by intramuscular injection weekly for 12 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Biochemical Recurrence of Prostate CancerTime frame: the 12-week treatment and the 3-month follow-up
- Change From Baseline in Overall Sexual Activity, Assessed Using Psychosexual Diary Questionnaire (PDQ) Question 4Time frame: Week 6, Week 12
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Johns Hopkins University
Baltimore, Maryland
Brigham and Women's Hospital
Boston, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.